hrp0084p3-1178 | Thyroid | ESPE2015

Short Stature with Lipodystrophy: Reminder of a Forgotten Syndrome

Kumar Rakesh , Rifkin Robin , Ehtisham Sarah

Background: The combination of various severe manifestations of hypothyroidism with pseudo muscular hypertrophy is called Kocher Debre Semelaigne syndrome (KDS). KDS is very rare in countries where newborn screening for hypothyroidism is in place. Most of the reports of KDS have come from India and developing countries with only a single report from Europe over last five decades. We present a 7-year-old boy from UK who had short stature and apparent partial lipodystrophy.<...

hrp0089fc2.5 | Bone, Growth Plate &amp; Mineral Metabolism 1 | ESPE2018

Radial ESWT Stimulates Longitudinal Bone Growth in Cultured Rat Fetal Metatarsal Bones

Ramesh Sowmya , Zaman Farasat , Madhuri Vrisha , Savendahl Lars

Background: Extracorporeal shock wave therapy (ESWT) is widely used in the clinic for non-union of fractures. However, effect of ESWT on longitudinal bone growth has not been well studied. We explored the in vitro and in vivo effects of low/high dose radial shock wave treatment (SWT) on growth plate (GP) cartilage. A positive or negative effect on growth could be harnessed for therapeutic growth modulation while no change establishes safety.<p class="abst...

hrp0086p2-p945 | Thyroid P2 | ESPE2016

Vitamin D Levels in Children with Hashimoto’s Thyroiditis: Before and after I-Thyroxine Therapy

Chaudhary Navendu , Kumar Rakesh , Sachdeva Naresh , Dayal Devi

Background: There is high prevalence of Vitamin D deficiency (VDD) in Hashimoto’s thyroiditis (HT) as reported in literature. However, it is uncertain whether VDD is a cause or effect of HT. The effect L-thyroxine replacement on vitamin D levels in children with HT has not been studied.Objective and hypotheses: To study vitamin D level of newly diagnosed children with HT and to observe the change in vitamin D level after L-thyroxine therapy.<p c...

hrp0084p2-457 | Growth | ESPE2015

Low Plasma Ghrelin Levels in Children with Severe Protein Energy Malnutrition

Harikrishnan V , Kumar Rakesh , Sachdeva Naresh , Dayal Devi

Background: Protein energy malnutrition (PEM) is a catabolic state with altered energy balance and anorexia. Ghrelin is a peptide hormone, produced by neuro-endocrine cells in the stomach, which stimulates appetite, increases food intake and growth hormone release. Although many trials have shown short term efficacy of ghrelin to increase appetite in anorexic and cachectic patients, data on the children with PEM is scarce.Objective and hypotheses: The st...

hrp0094p1-37 | Fat, Metabolism and Obesity A | ESPE2021

The effect of trans-palmitoleic acid on lipid accumulation and the fatty acid synthase gene expression in hepatocytes

Nourbakhsh Mitra , Farokh-Nezhad Ramesh , Razzaghy-Azar Maryam , Sharifi Roya , Yaghmaei Parichehreh , Nourbakhsh Mona ,

Introduction: Obesity is among the most prevalent health problems and is associated with increased risk of various metabolic disorders, including type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). Fatty acids comprise a major part of the lipids and have remarkable effect on cell biology. Trans fatty acids (tFAs) are generally a by-product of manufacturing of fats. However, naturally-produced tFAs that are found in milk and dairy products, are sugge...

hrp0086rfc10.4 | Perinatal Endocrinology | ESPE2016

Pharmacokinetics of Intravenous Glucagon in Children with Hyperinsulinaemic Hypoglycaemia

Shah Pratik , Rahman Sofia , Gilbert Clare , Morgan Kate , Hinchey Louise , Bech Paul , Amin Rakesh , Hussain Khalid

Background: Hyperinsulinaemic hypoglycaemia (HH) is one of the common causes of hypoglycaemia in infants and children. It can cause severe brain injury in children if not treated promptly. Diazoxide is first-line treatment for HH. Glucagon infusion is used in the management of children with HH. However it is unclear what dose of glucagon should be used in children.Objective and hypotheses: To evaluate the efficacy, safety and pharmacokinetics of intraven...

hrp0086p1-p556 | Perinatal Endocrinology P1 | ESPE2016

Pancreatic Glucagon Secretion is Severely Impaired and Somatostatin Secretion Unchanged in Patients with Hyperinsulinaemic Hypoglycaemia

Shah Pratik , Rahman Sofia , Gilbert Clare , Morgan Kate , Hinchey Louise , Bech Paul , Amin Rakesh , Hussain Khalid

Background: Hyperinsulinaemic hypoglycaemia (HH) is a common cause of hypoglycaemia in children. Glucagon is an important counter-regulatory hormone and the role of somatostatin is not known in children with HH.Objective and hypotheses: To understand the roles of glucagon and somatostatin in children with HH.Method: Children admitted for management of HH in our hospital were included in the study. Plasma insulin, glucagon and somat...

hrp0094p1-27 | Diabetes A | ESPE2021

The SARS-CoV-2 Pandemic Is Associated With Increased Severity Of Presentation Of Childhood Onset Type 1 Diabetes Mellitus: A Multicentre Study Of The First COVID-19 Wave

McGlacken-Byrne Sinead M , Drew Samantha EV , Turner Kelly , Peters Catherine , Amin Rakesh ,

Objective: Children are usually mildly affected by Severe Acute Respiratory Syndrome Coronavirus 2 infection (SARS-CoV-2, COVID-19). However, the pandemic has impacted negatively on children with non-COVID-19 diseases. We aimed to determine the impact of the COVID-19 pandemic on the presentation of newly diagnosed childhood-onset type 1 diabetes.Methods: This was a cross-sectional study conducted over a one-year period. ...

hrp0094p1-70 | Diabetes B | ESPE2021

Change in HbA1C predicts future abnormal Oral Glucose Tolerance Tests in children and adolescents with Cystic Fibrosis.

Aftab Sommayya , Ghauri Rooha Ijaz , Drew Samantha , Meek Hannah , Peters Catherine , Amin Rakesh ,

Background: Oral glucose tolerance test (OGTT) is the screening test of choice for Cystic Fibrosis Related Diabetes (CFRD). HbA1C is considered unreliable in diagnosing CFRD because of increased cell turn over in children and adolescents with Cystic Fibrosis (CF).Objective: To determine the validity of HbA1C as a predictive tool for future abnormal OGTT in CF.Material & Methods: Data were colle...

hrp0097fc12.1 | Thyroid | ESPE2023

Graves’ disease – are we just delaying the inevitable?

Stevens Chloe , Langham Shirley , Amin Rakesh , T Dattani Mehul , E Brain Caroline , J Peters Catherine

Background: The incidence of Graves’ disease in patients aged <15 years is estimated at 0.9 per 100,000. Parental anxiety around definitive treatment, timing of this around schooling and clinician confidence in long-term medical treatment often results in prolonged medical management. This audit aimed to assess the rates of remission, timing of definitive treatment and long-term medical management in children managed for Graves’ at a UK tertiary...